Drug Trial Radar · NCT07877038
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Oct 22, 2026
Primary completion
Apr 7, 2027
Study completion Apr 7, 2027
Sponsor
- Lead sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, non-randomized study to assess how DA-302168S is absorbed, distributed, metabolized, and eliminated after a single oral dose. The study includes three groups: subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), and healthy subjects matched by gender, age, and body mass index (BMI). It will also explore the relationship between baseline liver function measures and the pharmacokinetic (PK) parameters of DA-302168S, to support appropriate dosing recommendations for patients with liver impairment.
Conditions
- Obesity, Overweight
- T2DM (Type 2 Diabetes Mellitus)
Interventions
DA-302168SDrug
Small molecule GLP-1RA tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Plasma Concentration (Cmax) of DA-302168STime frame: Predose up to 72 hours postdose (D1 to D4)
- Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of DA-302168STime frame: Predose up to 72 hours postdose (D1 to D4)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.